Clinical Trial

Neoadjuvant Triple Therapy for Resectable HCC

Study acronym: TALENP001
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 15, 2024 (before its estimated February 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-arm, multi-center, prospective phase II trial aimed at evaluating the efficacy and safety of neoadjuvant therapy with transarterial chemoembolization (TACE) combined with lenvatinib and camrelizumab (triple therapy) in patients with resectable hepatocellular carcinoma (HCC). The study plans to enroll 20 patients. The primary endpoints are major pathological response (MPR) rate and safety, while the secondary endpoints are recurrence-free survival (RFS), objective response rate (ORR), R0 resection rate, and overall survival (OS).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-08-22; most recent amendment 2024-10-11.
Status change: Not Yet Recruiting → Recruiting 2024-09-23
Trial Details
NCT Number NCT06569498
Lead Sponsor Fujian Provincial Hospital
Conditions Resectable Hepatocellular Carcinoma
Enrollment 20 participants
Start Date 2024-09-30
Primary Completion 2026-02-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-10-15